Y-mAbs Therapeutics (YMAB) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB) from a hold rating to a sell rating in a research report released on Saturday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Separately, HC Wainwright initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, April 1st. They set a buy rating and a $36.00 target price on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $30.00.

YMAB traded down $0.07 during trading on Friday, reaching $21.31. 63,289 shares of the stock were exchanged, compared to its average volume of 112,551. The company has a market cap of $728.67 million and a price-to-earnings ratio of -14.21. Y-mAbs Therapeutics has a twelve month low of $15.17 and a twelve month high of $31.00. The company has a current ratio of 13.30, a quick ratio of 16.61 and a debt-to-equity ratio of 0.02.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.11). As a group, research analysts forecast that Y-mAbs Therapeutics will post -1.93 earnings per share for the current year.

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, May 13th. The shares were sold at an average price of $20.61, for a total transaction of $123,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc bought a new position in Y-mAbs Therapeutics during the third quarter worth $2,260,000. American International Group Inc. bought a new position in Y-mAbs Therapeutics during the fourth quarter worth $93,000. Strs Ohio bought a new position in Y-mAbs Therapeutics during the fourth quarter worth $38,000. Barclays PLC bought a new position in Y-mAbs Therapeutics during the fourth quarter worth $210,000. Finally, Vanguard Group Inc. bought a new position in Y-mAbs Therapeutics during the third quarter worth $2,260,000. 25.41% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.